[{"id":"ba5a9900-5311-4370-977a-05b3928feb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847453","created_at":"2021-04-19T12:52:34.348Z","updated_at":"2025-02-25T13:49:06.836Z","phase":"Phase 1","brief_title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","source_id_and_acronym":"NCT04847453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • MCL1 • BCL2L1 • SDC1 • BAX","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • MCL1 • BCL2L1 • SDC1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-20"},{"id":"7f3be9ed-280b-4ee8-a27b-1fa29dec3944","acronym":"","url":"https://clinicaltrials.gov/study/NCT03506373","created_at":"2025-02-25T16:37:04.959Z","updated_at":"2025-02-25T16:37:04.959Z","phase":"Phase 2","brief_title":"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia","source_id_and_acronym":"NCT03506373","lead_sponsor":"Mayo Clinic","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Ninlaro (ixazomib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 02/06/2023","primary_completion_date":" 02/06/2023","study_txt":" Completion: 03/11/2026","study_completion_date":" 03/11/2026","last_update_posted":"2025-02-07"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"de01f4b4-b380-45e4-a05f-0573156a9b1c","acronym":"AAML1031","url":"https://clinicaltrials.gov/study/NCT01371981","created_at":"2021-01-18T05:37:13.447Z","updated_at":"2025-02-25T16:51:07.072Z","phase":"Phase 3","brief_title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01371981 - AAML1031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1645","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-04"},{"id":"90e00a6d-bf2f-470b-9aff-9a2babcf60e1","acronym":"SWOG-S1304","url":"https://clinicaltrials.gov/study/NCT01903811","created_at":"2025-02-26T08:59:23.400Z","updated_at":"2025-02-26T08:59:23.400Z","phase":"Phase 2","brief_title":"S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma","source_id_and_acronym":"NCT01903811 - SWOG-S1304","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 11/21/2017","primary_completion_date":" 11/21/2017","study_txt":" Completion: 03/07/2019","study_completion_date":" 03/07/2019","last_update_posted":"2024-12-20"},{"id":"c2530d5f-2067-4089-83d8-8b338ff98d19","acronym":"","url":"https://clinicaltrials.gov/study/NCT06245629","created_at":"2025-02-26T11:14:39.219Z","updated_at":"2025-02-26T11:14:39.219Z","phase":"","brief_title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","source_id_and_acronym":"NCT06245629","lead_sponsor":"Uppsala University","biomarkers":" SLC1A5","pipe":"","alterations":" ","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/24/2024","start_date":" 11/24/2024","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-11-28"},{"id":"9ce1ae1c-3677-40b4-81f0-ce916a71323c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02633059","created_at":"2025-09-06T20:42:42.259Z","updated_at":"2025-09-06T20:42:42.259Z","phase":"Phase 1/2","brief_title":"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02633059","lead_sponsor":"Mayo Clinic","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2024-09-12"},{"id":"6c8187f2-a1a7-4e0d-9839-99324cab5154","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022939","created_at":"2023-09-05T18:12:25.015Z","updated_at":"2024-07-02T16:34:27.373Z","phase":"Phase 3","brief_title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","source_id_and_acronym":"NCT06022939","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/29/2030","primary_completion_date":" 07/29/2030","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2024-06-11"},{"id":"5077dab5-cc6d-4875-b03f-04b2ac602ed5","acronym":"NFL-BIOPAIN","url":"https://clinicaltrials.gov/study/NCT05781425","created_at":"2023-03-23T14:02:47.910Z","updated_at":"2024-07-02T16:34:37.446Z","phase":"","brief_title":"Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?","source_id_and_acronym":"NCT05781425 - NFL-BIOPAIN","lead_sponsor":"Odense University Hospital","biomarkers":" NEFL","pipe":"","alterations":" ","tags":["NEFL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"},{"id":"d888b6c9-4b44-4498-aef7-22dac96f744f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01163357","created_at":"2021-01-18T04:38:10.114Z","updated_at":"2024-07-02T16:35:00.426Z","phase":"Phase 1","brief_title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","source_id_and_acronym":"NCT01163357","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • sirolimus • melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/28/2011","start_date":" 01/28/2011","primary_txt":" Primary completion: 07/20/2019","primary_completion_date":" 07/20/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"8c229a43-88ef-4aa6-9cca-dad9d1af3b1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457142","created_at":"2021-01-18T17:02:40.865Z","updated_at":"2025-02-25T14:38:10.967Z","phase":"Phase 2","brief_title":"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy","source_id_and_acronym":"NCT03457142","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • CD28 • CD86","pipe":" | ","alterations":" CD28 expression • IL6 expression","tags":["IL6 • CD28 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • Orencia (abatacept)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/11/2018","start_date":" 09/11/2018","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-05-16"},{"id":"85f3a1ec-2757-468c-a247-bc4c8aeb7a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01941316","created_at":"2021-01-18T08:47:22.528Z","updated_at":"2024-07-02T16:35:04.683Z","phase":"Phase 1/2","brief_title":"Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients","source_id_and_acronym":"NCT01941316","lead_sponsor":"Cancer Research and Biostatistics Clinical Trials Consortium","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • carfilzomib"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 12/31/2018","primary_completion_date":" 12/31/2018","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2024-05-09"},{"id":"8c189e73-7839-42ec-89f2-d58afc05f72f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04177823","created_at":"2021-01-18T20:22:29.877Z","updated_at":"2024-07-02T16:35:08.515Z","phase":"Phase 1","brief_title":"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","source_id_and_acronym":"NCT04177823","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8","pipe":" | ","alterations":" CD38 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-04-19"},{"id":"a47b9baf-315f-4d17-8189-36a9e437a098","acronym":"BORXPTEN","url":"https://clinicaltrials.gov/study/NCT06029998","created_at":"2023-09-08T20:10:19.869Z","updated_at":"2024-07-02T16:35:14.989Z","phase":"Phase 2","brief_title":"Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion","source_id_and_acronym":"NCT06029998 - BORXPTEN","lead_sponsor":"University of Utah","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN deletion","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-03-13"},{"id":"71b2abcb-8431-493c-a6af-7ff2db093e87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03399539","created_at":"2021-01-18T16:46:36.555Z","updated_at":"2024-07-02T16:35:16.514Z","phase":"Phase 1","brief_title":"Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03399539","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 12/20/2021","primary_completion_date":" 12/20/2021","study_txt":" Completion: 02/23/2024","study_completion_date":" 02/23/2024","last_update_posted":"2024-03-04"},{"id":"cecdbaf1-ddd6-42e8-84b3-c89f7f4d1267","acronym":"BORTEM-17","url":"https://clinicaltrials.gov/study/NCT03643549","created_at":"2021-07-05T17:16:33.314Z","updated_at":"2024-07-02T16:35:17.017Z","phase":"Phase 1/2","brief_title":"Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)","source_id_and_acronym":"NCT03643549 - BORTEM-17","lead_sponsor":"Haukeland University Hospital","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/30/2018","start_date":" 08/30/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-29"},{"id":"9c1f7fff-bdbd-42f6-b86e-29192b0576bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05850286","created_at":"2023-05-09T14:04:26.586Z","updated_at":"2024-07-02T16:35:18.522Z","phase":"Phase 2","brief_title":"A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities","source_id_and_acronym":"NCT05850286","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" TP53 • SDC1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-02-20"},{"id":"eb78ca75-84dc-42fc-9d06-f04752556eba","acronym":"NCI-2018-01292","url":"https://clinicaltrials.gov/study/NCT03587662","created_at":"2021-01-18T17:38:43.114Z","updated_at":"2024-07-02T16:35:23.938Z","phase":"Phase 2","brief_title":"Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03587662 - NCI-2018-01292","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCB1 negative","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCB1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • doxorubicin hydrochloride • Ninlaro (ixazomib) • daunorubicin • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/17/2018","start_date":" 08/17/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"712d60d7-437e-4110-862c-d16292e6a321","acronym":"","url":"https://clinicaltrials.gov/study/NCT03506360","created_at":"2021-01-18T17:15:42.413Z","updated_at":"2024-07-02T16:35:24.142Z","phase":"Phase 2","brief_title":"Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03506360","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ninlaro (ixazomib) • dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 11/14/2019","primary_completion_date":" 11/14/2019","study_txt":" Completion: 12/10/2020","study_completion_date":" 12/10/2020","last_update_posted":"2024-01-09"},{"id":"6c9623a6-4573-485b-b022-26e539880a69","acronym":"A061202","url":"https://clinicaltrials.gov/study/NCT02004275","created_at":"2021-01-18T09:09:12.624Z","updated_at":"2025-02-25T14:34:26.703Z","phase":"Phase 1/2","brief_title":"Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02004275 - A061202","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CYP1A2","pipe":" | ","alterations":" Chr t(14;16) • Chr del(1p)","tags":["CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(14;16) • Chr del(1p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Ninlaro (ixazomib) • dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2023-12-01"},{"id":"ef987b75-152a-4c88-b4b8-861289283719","acronym":"","url":"https://clinicaltrials.gov/study/NCT01142401","created_at":"2021-01-18T04:32:37.835Z","updated_at":"2024-07-02T16:35:28.091Z","phase":"Phase 2","brief_title":"Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT01142401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" ER positive","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 118","initiation":"Initiation: 05/26/2010","start_date":" 05/26/2010","primary_txt":" Primary completion: 07/30/2015","primary_completion_date":" 07/30/2015","study_txt":" Completion: 01/08/2021","study_completion_date":" 01/08/2021","last_update_posted":"2023-11-27"},{"id":"7465a53d-edcc-499b-8a80-50f901ea6413","acronym":"HO147SMM","url":"https://clinicaltrials.gov/study/NCT03673826","created_at":"2021-01-18T18:01:13.776Z","updated_at":"2024-07-02T16:35:30.805Z","phase":"Phase 2","brief_title":"Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM","source_id_and_acronym":"NCT03673826 - HO147SMM","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" PTPRC • NCAM1","pipe":"","alterations":" ","tags":["PTPRC • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 11/19/2018","start_date":" 11/19/2018","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-11-01"},{"id":"79b87011-f88c-4a4b-b57c-fa97cf0c37d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02308280","created_at":"2022-01-21T21:58:53.578Z","updated_at":"2024-07-02T16:35:32.703Z","phase":"Phase 2","brief_title":"Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients","source_id_and_acronym":"NCT02308280","lead_sponsor":"Maisonneuve-Rosemont Hospital","biomarkers":" HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • melphalan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 09/27/2018","primary_completion_date":" 09/27/2018","study_txt":" Completion: 09/27/2023","study_completion_date":" 09/27/2023","last_update_posted":"2023-10-19"},{"id":"a0bd09e4-f67d-438b-b849-d3cd946ef7c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03616782","created_at":"2021-01-18T17:46:16.289Z","updated_at":"2025-02-25T14:51:05.155Z","phase":"Phase 2","brief_title":"Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)","source_id_and_acronym":"NCT03616782","lead_sponsor":"Ho Sup Lee","biomarkers":" CD20 • CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib)"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-10-06"}]